Amgen announced that detailed results of the Repatha (evolocumab) cardiovascular outcomes trial will be presented, as well as new data from across the cardiovascular portfolio, at the American College of Cardiology 66th Annual Scientific Session (ACC.17) in Washington, D.C., March 17-19, 2017.
Detailed results from the Repatha cardiovascular outcomes trial (FOURIER) will be featured as a late-breaking oral presentation on Friday, March 17 at 9 a.m. ET. A second late-breaking oral presentation, the Repatha cognitive function trial (EBBINGHAUS), will be presented on Saturday, March 18 at 9 a.m. ET. Live audio and video of the presentations will be webcast over the internet simultaneously with the presentations. Amgen announced in February that FOURIER met its primary composite endpoint and key secondary composite endpoint and EBBINGHAUS met its primary endpoint.
“As cardiovascular disease remains the leading health burden in the world, we sought to answer whether adding Repatha would provide further risk reduction for patients who are already well-treated with statins,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “The data from this large cardiovascular outcomes trial will provide a new understanding of the role that Repatha plays in the lives of the millions of people living with uncontrolled high cholesterol.”
Additionally, data from two separate analyses will explore prescription rejection rates and access barriers for PCSK9 inhibitors, including a comparison of the patient characteristics amongst those approved and denied access.
Harper continued, “As we prepare to share our outcomes data with the cardiovascular community, patients continue to face unacceptable barriers to getting the additional LDL lowering that Repatha can provide, despite their physician’s treatment recommendations.”
Filed Under: Drug Discovery
